Skip to main content
Top
Published in: Breast Cancer Research 1/2015

Open Access 01-12-2015 | Research article

Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort

Authors: Adam R. Brentnall, Elaine F. Harkness, Susan M. Astley, Louise S. Donnelly, Paula Stavrinos, Sarah Sampson, Lynne Fox, Jamie C. Sergeant, Michelle N. Harvie, Mary Wilson, Ursula Beetles, Soujanya Gadde, Yit Lim, Anil Jain, Sara Bundred, Nicola Barr, Valerie Reece, Anthony Howell, Jack Cuzick, D. Gareth R. Evans

Published in: Breast Cancer Research | Issue 1/2015

Login to get access

Abstract

Introduction

The Predicting Risk of Cancer at Screening study in Manchester, UK, is a prospective study of breast cancer risk estimation. It was designed to assess whether mammographic density may help in refinement of breast cancer risk estimation using either the Gail model (Breast Cancer Risk Assessment Tool) or the Tyrer-Cuzick model (International Breast Intervention Study model).

Methods

Mammographic density was measured at entry as a percentage visual assessment, adjusted for age and body mass index. Tyrer-Cuzick and Gail 10-year risks were based on a questionnaire completed contemporaneously. Breast cancers were identified at the entry screen or shortly thereafter. The contribution of density to risk models was assessed using odds ratios (ORs) with profile likelihood confidence intervals (CIs) and area under the receiver operating characteristic curve (AUC). The calibration of predicted ORs was estimated as a percentage [(observed vs expected (O/E)] from logistic regression.

Results

The analysis included 50,628 women aged 47–73 years who were recruited between October 2009 and September 2013. Of these, 697 had breast cancer diagnosed after enrolment. Median follow-up was 3.2 years. Breast density [interquartile range odds ratio (IQR-OR) 1.48, 95 % CI 1.34–1.63, AUC 0.59] was a slightly stronger univariate risk factor than the Tyrer-Cuzick model [IQR-OR 1.36 (95 % CI 1.25–1.48), O/E 60 % (95 % CI 44–74), AUC 0.57] or the Gail model [IQR-OR 1.22 (95 % CI 1.12–1.33), O/E 46 % (95 % CI 26–65 %), AUC 0.55]. It continued to add information after allowing for Tyrer-Cuzick [IQR-OR 1.47 (95 % CI 1.33–1.62), combined AUC 0.61] or Gail [IQR-OR 1.45 (95 % CI 1.32–1.60), combined AUC 0.59].

Conclusions

Breast density may be usefully combined with the Tyrer-Cuzick model or the Gail model.
Appendix
Available only for authorised users
Literature
1.
go back to reference Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, et al. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16:446.CrossRefPubMedPubMedCentral Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, et al. Risk determination and prevention of breast cancer. Breast Cancer Res. 2014;16:446.CrossRefPubMedPubMedCentral
2.
go back to reference Smith RA, Manassaram-Baptiste D, Brooks D, Cokkinides V, Doroshenk D, Saslow D, et al. Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2014;64:30–51.CrossRefPubMed Smith RA, Manassaram-Baptiste D, Brooks D, Cokkinides V, Doroshenk D, Saslow D, et al. Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2014;64:30–51.CrossRefPubMed
3.
go back to reference Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, Stavrinos P, et al. Breast cancer risk in young women in the National Breast Screening Programme: implications for applying NICE guidelines for additional screening and chemoprevention. Cancer Prev Res (Phila). 2014;7:993–1001.CrossRef Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, Stavrinos P, et al. Breast cancer risk in young women in the National Breast Screening Programme: implications for applying NICE guidelines for additional screening and chemoprevention. Cancer Prev Res (Phila). 2014;7:993–1001.CrossRef
4.
go back to reference Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.CrossRefPubMed Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.CrossRefPubMed
5.
go back to reference Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30.CrossRefPubMed Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30.CrossRefPubMed
6.
go back to reference Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541–8.CrossRefPubMed Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541–8.CrossRefPubMed
7.
go back to reference Gail MH, Mai PL. Comparing breast cancer risk assessment models. J Natl Cancer Inst. 2010;102:665–8.CrossRefPubMed Gail MH, Mai PL. Comparing breast cancer risk assessment models. J Natl Cancer Inst. 2010;102:665–8.CrossRefPubMed
8.
go back to reference Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003;40:807–14.CrossRefPubMedPubMedCentral Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet. 2003;40:807–14.CrossRefPubMedPubMedCentral
9.
go back to reference Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res. 2012;14:R144.CrossRefPubMedPubMedCentral Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. Breast Cancer Res. 2012;14:R144.CrossRefPubMedPubMedCentral
10.
go back to reference Assi V, Warwick J, Cuzick J, Duffy SW. Clinical and epidemiological issues in mammographic density. Nat Rev Clin Oncol. 2011;9:33–40.CrossRefPubMed Assi V, Warwick J, Cuzick J, Duffy SW. Clinical and epidemiological issues in mammographic density. Nat Rev Clin Oncol. 2011;9:33–40.CrossRefPubMed
11.
go back to reference American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS). 4th ed. Reston, VA: American College of Radiology; 2003. American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS). 4th ed. Reston, VA: American College of Radiology; 2003.
12.
go back to reference Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008;148:337–47.CrossRefPubMedPubMedCentral Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008;148:337–47.CrossRefPubMedPubMedCentral
13.
go back to reference Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat. 2005;94:115–22.CrossRefPubMed Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat. 2005;94:115–22.CrossRefPubMed
14.
go back to reference Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98:1204–14.CrossRefPubMed Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98:1204–14.CrossRefPubMed
15.
go back to reference McCormack VA, Santos SI. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:1159–69.CrossRefPubMed McCormack VA, Santos SI. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:1159–69.CrossRefPubMed
16.
go back to reference Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case–control study. J Natl Cancer Inst. 2011;103:744–52.CrossRefPubMed Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case–control study. J Natl Cancer Inst. 2011;103:744–52.CrossRefPubMed
17.
go back to reference Kim J, Han W, Moon HG, Ahn SK, Shin HC, You JM, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res. 2012;14:R102. A published erratum appears in Breast Cancer Res. 2012;14:403.CrossRefPubMedPubMedCentral Kim J, Han W, Moon HG, Ahn SK, Shin HC, You JM, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res. 2012;14:R102. A published erratum appears in Breast Cancer Res. 2012;14:403.CrossRefPubMedPubMedCentral
18.
go back to reference Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol. 2013;31:2249–56.CrossRefPubMedPubMedCentral Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol. 2013;31:2249–56.CrossRefPubMedPubMedCentral
19.
go back to reference Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst. 2006;98:1215–26.CrossRefPubMed Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst. 2006;98:1215–26.CrossRefPubMed
20.
go back to reference Warwick J, Birke H, Stone J, Warren RM, Pinney E, Brentnall AR, et al. Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. Breast Cancer Res. 2014;16:451.CrossRefPubMedPubMedCentral Warwick J, Birke H, Stone J, Warren RM, Pinney E, Brentnall AR, et al. Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. Breast Cancer Res. 2014;16:451.CrossRefPubMedPubMedCentral
21.
go back to reference Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. Phys Med Biol. 1994;39:1629–38.CrossRefPubMed Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. Phys Med Biol. 1994;39:1629–38.CrossRefPubMed
22.
go back to reference Sergeant JC, Walshaw L, Wilson M, Seed S, Barr N, Beetles U, et al. Same task, same observers, different values: the problem with visual assessment of breast density. In: Proc SPIE Int Soc Opt Eng 8673, Medical Imaging 2013: Image Perception, Observer Performance, and Technology Assessment, 86730T; 28 Mar 2013. doi:10.1117/12.2006778. Sergeant JC, Walshaw L, Wilson M, Seed S, Barr N, Beetles U, et al. Same task, same observers, different values: the problem with visual assessment of breast density. In: Proc SPIE Int Soc Opt Eng 8673, Medical Imaging 2013: Image Perception, Observer Performance, and Technology Assessment, 86730T; 28 Mar 2013. doi:10.​1117/​12.​2006778.
23.
go back to reference Evans DGR, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham S, et al. Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. Cancer Prev Res (Phila). 2012;5:943–51.CrossRef Evans DGR, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham S, et al. Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. Cancer Prev Res (Phila). 2012;5:943–51.CrossRef
24.
go back to reference Gilbert FJ, Astley SM, McGee MA, Gillan MG, Boggis CR, Griffiths PM, et al. Single reading with computer-aided detection and double reading of screening mammograms in the United Kingdom National Breast Screening Program. Radiology. 2006;241:47–53.CrossRefPubMed Gilbert FJ, Astley SM, McGee MA, Gillan MG, Boggis CR, Griffiths PM, et al. Single reading with computer-aided detection and double reading of screening mammograms in the United Kingdom National Breast Screening Program. Radiology. 2006;241:47–53.CrossRefPubMed
25.
go back to reference National Health Service Breast Screening Programme (NHSBSP). Guidelines for pathology reporting of breast disease. NHSBSP Publication 58. Sheffield, UK: NHS Screening Programmes; 2005. National Health Service Breast Screening Programme (NHSBSP). Guidelines for pathology reporting of breast disease. NHSBSP Publication 58. Sheffield, UK: NHS Screening Programmes; 2005.
26.
go back to reference Crowder MJ, Hand DJ. Analysis of repeated measures. London: Chapman & Hall; 1990. Crowder MJ, Hand DJ. Analysis of repeated measures. London: Chapman & Hall; 1990.
28.
go back to reference DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1998;44:837–45.CrossRef DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1998;44:837–45.CrossRef
29.
go back to reference R Core Team. R. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2012. R Core Team. R. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2012.
30.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358:1389–99.CrossRef Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet. 2001;358:1389–99.CrossRef
31.
go back to reference Sperrin M, Bardwell L, Sergeant JC, Astley S, Buchan I. Correcting for rater bias in scores on a continuous scale, with application to breast density. Stat Med. 2013;32:4666–78.CrossRefPubMed Sperrin M, Bardwell L, Sergeant JC, Astley S, Buchan I. Correcting for rater bias in scores on a continuous scale, with application to breast density. Stat Med. 2013;32:4666–78.CrossRefPubMed
32.
go back to reference Duffy SW, Nagtegaal ID, Astley SM, Gillan MG, McGee MA, Boggis CR, et al. Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view. Breast Cancer Res. 2008;10:R64.CrossRefPubMedPubMedCentral Duffy SW, Nagtegaal ID, Astley SM, Gillan MG, McGee MA, Boggis CR, et al. Visually assessed breast density, breast cancer risk and the importance of the craniocaudal view. Breast Cancer Res. 2008;10:R64.CrossRefPubMedPubMedCentral
Metadata
Title
Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort
Authors
Adam R. Brentnall
Elaine F. Harkness
Susan M. Astley
Louise S. Donnelly
Paula Stavrinos
Sarah Sampson
Lynne Fox
Jamie C. Sergeant
Michelle N. Harvie
Mary Wilson
Ursula Beetles
Soujanya Gadde
Yit Lim
Anil Jain
Sara Bundred
Nicola Barr
Valerie Reece
Anthony Howell
Jack Cuzick
D. Gareth R. Evans
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2015
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-015-0653-5

Other articles of this Issue 1/2015

Breast Cancer Research 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine